Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Says it has raised GBP340,000 through the placing of 100,000 shares at 340p each. The financing will be dedicated to the clinical trial of its HG-CT-1 drug, which is used for treatment of acute myeloid leukaemia in adults. The first patient for the trial has been recruited and is being tested to ensure they satisfy the clinic protocol.
Current stock price: 393.75 pence, down 1.6% in London on Wednesday morning
12-month change: down 55%
By Lydia Doye, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights reserved.
Hemogenyx (HEMO)
